Unlock Premium for Just $9.99/Month – Special Launch Offer, Limited Time Only
Get Premium
BGLC BioNexus Gene Lab Corp
- Stocks
- Healthcare
- NASDAQ: BGLC
Price (delayed)
$2.85
Market cap
$5.12M
P/E Ratio
N/A
Dividend/share
N/A
EPS
-$0.9
Enterprise value
$3.77M
Highlights
The EPS has grown by 46% YoY
The net income has plunged by 70% from the previous quarter but it has grown by 39% YoY
The debt has surged by 55% year-on-year but it has declined by 7% since the previous quarter
The quick ratio has declined by 27% year-on-year and by 23% since the previous quarter
BioNexus Gene Lab's equity has decreased by 14% YoY and by 11% QoQ
Key stats
What are the main financial stats of BGLC
Market
Valuations
Earnings
Shares outstanding
1.8M
Market cap
$5.12M
Enterprise value
$3.77M
Price to earnings (P/E)
N/A
Price to book (P/B)
0.62
Price to sales (P/S)
0.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.4
Revenue
$9.51M
Gross profit
$1.29M
Operating income
-$3.65M
Net income
-$1.6M
EBIT
-$1.57M
EBITDA
-$1.42M
Free cash flow
-$2.46M
Per share
Balance sheet
Liquidity
EPS
-$0.9
EPS diluted
-$0.9
Free cash flow per share
-$1.38
Book value per share
$4.63
Revenue per share
$5.34
TBVPS
$5.86
Total assets
$10.43M
Total liabilities
$2.11M
Debt
$227,731
Equity
$8.32M
Working capital
$5.48M
Debt to equity
0.03
Current ratio
3.81
Quick ratio
3.05
Net debt/EBITDA
0.95
Margins
Efficiency
Dividend
EBITDA margin
-14.9%
Gross margin
13.6%
Net margin
-16.8%
Operating margin
-38.3%
Return on assets
-14.6%
Return on equity
-17.5%
Return on invested capital
-21%
Return on capital employed
-18.6%
Return on sales
-16.5%
Dividend yield
N/A
DPS
N/A
Payout ratio
N/A
BGLC stock price
How has the BioNexus Gene Lab stock price performed over time
Intraday
-6.25%
1 week
6.74%
1 month
6.74%
1 year
-50%
YTD
1.79%
QTD
20.76%
Financial performance
How have BioNexus Gene Lab's revenue and profit performed over time
Revenue
$9.51M
Gross profit
$1.29M
Operating income
-$3.65M
Net income
-$1.6M
Gross margin
13.6%
Net margin
-16.8%
The net income has plunged by 70% from the previous quarter but it has grown by 39% YoY
The net margin has dropped by 65% since the previous quarter but it has grown by 38% year-on-year
The operating income has dropped by 61% since the previous quarter and by 18% year-on-year
BioNexus Gene Lab's operating margin has shrunk by 56% QoQ and by 22% YoY
Price vs fundamentals
How does BGLC's price correlate with its fundamentals
Growth
What is BioNexus Gene Lab's growth rate over time
Valuation
What is BioNexus Gene Lab stock price valuation
P/E
N/A
P/B
0.62
P/S
0.53
EV/EBIT
N/A
EV/EBITDA
N/A
EV/Sales
0.4
The EPS has grown by 46% YoY
The P/B is 31% lower than the last 4 quarters average of 0.9
BioNexus Gene Lab's equity has decreased by 14% YoY and by 11% QoQ
BGLC's price to sales (P/S) is 41% less than its last 4 quarters average of 0.9
The revenue is up by 2.7% since the previous quarter but it has declined by 2.7% year-on-year
Efficiency
How efficient is BioNexus Gene Lab business performance
The return on equity has dropped by 77% since the previous quarter but it rose by 47% year-on-year
The return on invested capital has dropped by 76% since the previous quarter but it has surged by 50% year-on-year
The ROA has shrunk by 74% QoQ but it rose by 46% YoY
The ROS has plunged by 70% from the previous quarter but it has grown by 38% YoY
Dividends
What is BGLC's dividend
DPS
N/A
Dividend yield
N/A
Payout ratio
N/A
There are no recent dividends present for BGLC.
Financial health
How did BioNexus Gene Lab financials performed over time
BioNexus Gene Lab's total liabilities has increased by 31% QoQ and by 21% YoY
The quick ratio has declined by 27% year-on-year and by 23% since the previous quarter
The debt is 97% smaller than the equity
The debt has surged by 55% year-on-year but it has declined by 7% since the previous quarter
The company's debt to equity has surged by 50% YoY
All financial data is based on trailing twelve months (TTM) periods - updated quarterly, unless otherwise specified.